Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 19:7. Implied volatility suggests the market is anticipating a move near 7.5%, or 95c, after results are released. Median move over the past eight quarters is 8.8%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz
- Capricor Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating
- Capricor Therapeutics’ Deramiocel Receives FDA Priority Review
- Capricor announces FDA acceptance, Priority Review for deramiocel BLA
- CAPR Upcoming Earnings Report: What to Expect?